Brokers Issue Forecasts for NAMS FY2026 Earnings

NewAmsterdam Pharma (NASDAQ:NAMS) – Cantor Fitzgerald issued their FY2026 earnings per share estimates for NewAmsterdam Pharma in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse expects that the company will earn ($2.25) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $42.00 target price on the stock. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.75) per share.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.04). The company had revenue of $2.98 million during the quarter, compared to analyst estimates of $1.46 million.

A number of other equities research analysts also recently issued reports on NAMS. Scotiabank increased their price target on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Thursday, February 27th. Needham & Company LLC reduced their price target on NewAmsterdam Pharma from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, May 8th. Stifel Nicolaus initiated coverage on NewAmsterdam Pharma in a research report on Tuesday. They set a “buy” rating and a $44.00 price target on the stock. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Friday, May 30th. Finally, UBS Group set a $41.00 price target on NewAmsterdam Pharma in a research report on Monday, March 3rd. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $43.00.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS opened at $20.50 on Tuesday. The company has a market capitalization of $2.30 billion, a P/E ratio of -10.90 and a beta of -0.03. NewAmsterdam Pharma has a 1 year low of $14.06 and a 1 year high of $27.29. The business’s 50 day simple moving average is $17.99 and its 200 day simple moving average is $20.86.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Quarry LP bought a new position in shares of NewAmsterdam Pharma in the 1st quarter valued at $25,000. GF Fund Management CO. LTD. bought a new position in shares of NewAmsterdam Pharma in the 4th quarter valued at $50,000. National Bank of Canada FI bought a new position in shares of NewAmsterdam Pharma in the 4th quarter valued at $51,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of NewAmsterdam Pharma in the 4th quarter valued at $80,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of NewAmsterdam Pharma by 130.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company’s stock valued at $123,000 after acquiring an additional 3,390 shares during the last quarter. 89.89% of the stock is currently owned by institutional investors.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, Director James N. Topper purchased 1,135 shares of the company’s stock in a transaction dated Wednesday, March 26th. The stock was bought at an average cost of $22.49 per share, for a total transaction of $25,526.15. Following the purchase, the director now owns 3,013,569 shares of the company’s stock, valued at approximately $67,775,166.81. The trade was a 0.04% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 20.84% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.